The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors.
 
Todd Michael Bauer
Research Funding - MedImmune (Inst)
 
Young Kwang Chae
Research Funding - MedImmune (Inst)
 
Sandip Patel
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - MedImmune (Inst)
 
Sandra P. D'Angelo
Research Funding - MedImmune (Inst)
 
George R. Blumenschein
Honoraria - Bayer; Bristol-Myers Squibb; Celgene; Novartis
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Novartis
Research Funding - MedImmune (Inst)
Travel, Accommodations, Expenses - Bayer; Celgene
 
Jonathan Norton
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
 
Carol Pound
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Mark C. Lanasa
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; Genentech
Research Funding - Celgene (Inst)
 
Brendan D. Curti
Honoraria - Prometheus
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Agonox; Prometheus